2A7A-LP2

2A7A-LP2 is an **antibody-drug conjugate (ADC)** composed of a mouse monoclonal antibody (clone 2A7A) targeting **TM4SF1** (Transmembrane 4 L six family member 1), conjugated via a non-cleavable maleimidocaproyl (Mc) linker to the cytotoxic payload **LP2** (a water-soluble dolastatin analog, chemical name mc-3377) derived from auristatin. TM4SF1 is highly expressed on many carcinoma cells and the endothelial cells lining tumor vasculature, making it a promising dual-action anticancer target. The mechanism of action involves antibody-mediated internalization and lysosomal degradation of the ADC, releasing the cytotoxic drug intracellularly. In preclinical models, 2A7A-LP2 demonstrated potent anticancer activity and vascular targeting without significant toxicity. Developed as a surrogate for anti-mouse TM4SF1 to complement humanized ADC studies, its primary indication is as an experimental therapy for TM4SF1-positive cancers.[1][4][5]